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Background: Patient-reported outcomes are integral in benefit–risk assessments of new treatment regimens. The PALOMA-2
study provides the largest body of evidence for patient-reported health-related quality of life (QOL) for patients with metastatic
breast cancer (MBC) receiving first-line endocrine-based therapy (palbociclib plus letrozole and letrozole alone).
Patients and methods: Treatment-naı¨ve postmenopausal women with estrogen receptor-positive (ERþ)/human epidermal
growth factor receptor 2-negative (HER2) MBC were randomized 2 : 1 to palbociclib plus letrozole (n¼ 444) or placebo plus
letrozole (n¼ 222). Patient-reported outcomes were assessed at baseline, day 1 of cycles 2 and 3, and day 1 of every other cycle
from cycle 5 using the Functional Assessment of Cancer Therapy (FACT)-Breast and EuroQOL 5 dimensions (EQ-5D)
questionnaires.
Results: As of 26 February 2016, the median duration of follow-up was 23months. Baseline scores were comparable between
the two treatment arms. No significant between-arm differences were observed in change from baseline in FACT-Breast Total,
FACT-General Total, or EQ-5D scores. Significantly greater improvement in pain scores was observed in the palbociclib plus
letrozole arm (0.256 versus0.098; P¼ 0.0183). In both arms, deterioration of FACT-Breast Total score was significantly
delayed in patients without progression versus those with progression and patients with partial or complete response versus
those without. No significant difference was observed in FACT-Breast and EQ-5D index scores in patients with and without
neutropenia.
Conclusions: Overall, women with MBC receiving first-line endocrine therapy have a good QOL. The addition of palbociclib to
letrozole maintains health-related QOL and improves pain scores in treatment-naı¨ve postmenopausal patients with ERþ/HER2
MBC compared with letrozole alone. Significantly greater delay in deterioration of health-related QOL was observed in patients
without progression versus those who progressed and in patients with an objective response versus non-responders.
ClinicalTrials.gov: NCT01740427 (https://clinicaltrials.gov/ct2/show/NCT01740427)
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Introduction
Endocrine therapy is the primary treatment option for patients
with treatment-naı¨ve estrogen receptor-positive (ERþ)/human
epidermal growth factor receptor 2-negative (HER2) metastatic
breast cancer (MBC). However, all patients eventually develop
tumor progression or have primary tumor resistance to endo-
crine treatments. Improving response and prolonging the dur-
ation of response to endocrine-based therapy while maintaining
or improving quality of life (QOL) is an important treatment
goal. The addition of agents targeted to pathways contributing to
resistance may improve response and delay progression, but it is
critical to understand both the safety profile and the impact of
these therapies on QOL [1, 2]. As such, patient-reported out-
comes (PROs) are an integral component of benefit–risk assess-
ments in the evaluation of new treatment regimens.
Palbociclib (Ibrance, Pfizer, New York, NY) is an orally bioavail-
able small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4
and 6 [3]. The recently reported results from the primary end point
of the phase III study (PALOMA-2) demonstrated a significant im-
provement in progression-free survival (PFS) with palbociclib plus
letrozole [median 24.8 versus 14.5months; hazard ratio (HR): 0.58;
95% confidence interval (CI), 0.46–0.72; P< 0.001] versus placebo
plus letrozole [4]. The main objective of the current report describes
the impact of palbociclib and letrozole combination therapy on
patient-reportedQOL in PALOMA-2 (NCT01740427).
Patients and methods
Study design and participants
PALOMA-2 is an international (17 countries), randomized, double-
blind, placebo-controlled, parallel-group, phase III study in which post-
menopausal women with ERþ/HER2– advanced/metastatic breast can-
cer who had not received systemic anticancer treatment of advanced
disease (ie, treatment-naı¨ve) were randomized 2 : 1 to palbociclib plus
letrozole (n¼ 444) or placebo plus letrozole (n¼ 222). All randomized
patients received study therapy (supplementary Figure S1, available at
Annals of Oncology online); additional methods are published elsewhere
[4]. The study was carried out in compliance with ethical principles out-
lined in the Declaration of Helsinki; the study protocol was approved by
local review boards at each investigational center.
Treatment
Palbociclib or placebo was administered orally 125mg daily for 21 days
of every 28-day cycle followed by 7 days off. Letrozole was administered
orally 2.5mg on a continuous daily dosing schedule.
Patient-reported outcomes
Patient-reported health-related QOL (HRQOL) outcomes, a secondary
objective in the PALOMA-2 trial, were assessed using the fully validated
Functional Assessment of Cancer Therapy-Breast (FACT-B) and
EuroQOL 5 dimensions (EQ-5D) questionnaires at baseline, day 1 of
cycles 2 and 3, and day 1 of every alternate cycle from cycle 5 until disease
progression or end of study treatment [5–7]. Patients completed the self-
assessment questionnaires at the study site. The FACT-B was chosen as it
is a well-validated questionnaire to assess breast cancer-specific HRQOL.
The majority of patients in the validation study for this instrument had
stage IV breast cancer; hence, the instrument was considered appropriate
to assess HRQOL in the PALOMA-2 study.
The FACT-B (version 4, 1997) measures multidimensional breast
cancer-specific HRQOL using a 37-item self-reporting instrument
containing the 27-question FACT-General (FACT-G) survey and a 10-
question breast cancer-additional concerns scale [5]. Patients are asked
to respond to each question on a Likert scale where 0¼ not at all, 1¼ a
little bit, 2¼ somewhat, 3¼ quite a bit, and 4¼ very much. FACT-B pro-
duces five subscale scores that reflect the patient’s QOL: physical well-
being (PWB), social/family well-being (SWB), emotional well-being
(EWB), functional well-being (FWB), and a breast cancer subscale
(BCS). The BCS was calculated using the first 9 of the 10 items in our ana-
lyses with the last item assessing pain excluded as recommended by the
scoring guidelines for FACT-B v4.0. These subscale scores were used to de-
rive three assessment outcomes—FACT-B total score, FACT-G total score,
and FACT-BTrial Outcome Index (TOI), which are defined as follows:
FACT-B total score ¼ PWB þ SWB þ EWB þ FWB þ BCS
FACT-G total score ¼ PWB þ SWB þ EWB þ FWB
TOI score ¼ PWB þ FWB þ BCS
Subscale scores were calculated if over 50% of the component individ-
ual items in that subscale are non-missing; the total scores were calculated
if over 80% of the component items are non-missing and all the compo-
nent subscales have valid scores.
A higher score in any FACT-B assessment indicates better QOL. A
meaningful change in QOL is defined as a change in baseline score equal
to or greater than the established minimally important differences:
FACT-G¼ 5–6 points and FACT-B¼ 7–8 points [8]. The tenth item of
the BCS (P2) assessing severity of pain in certain parts of the body was
analyzed as an individual item separate from the BCS. A higher raw score
on the pain item indicates higher pain severity.
The EQ-5D questionnaire [6] is composed of a 5-item health status
measure and a visual analog scale (VAS) administered separately and
used to generate two different scores, the EQ-5D index and the VAS gen-
eral health status. The EQ-5D index score is based on answers to a 5-item
questionnaire evaluating mobility, self-care, usual activities, pain, dis-
comfort, and anxiety/depression. Answers received a score ranging from
1 to 3, depending on whether patients perceived no problems (¼1), some
problems (¼2), or extreme problems (¼3) in that aspect of their health.
Summary scores were calculated using an algorithm based on societal
preferences from general population-based valuation studies in the UK
(0¼ death, 1.0¼ perfect health) [6]. A higher EQ-5D index score indi-
cated a better QOL. The EQ-5D VAS generates a single health status score
in which patients are asked to rate their current health on a VAS ranging
from 100 (best imaginable health state) to 0 (worst imaginable health
state).
Statistical analyses
PRO analyses were based on the PRO-evaluable population (i.e., patients
in the intent-to-treat [ITT] population with a baseline and1 post-
baseline assessment before the end of study treatment). Completion rates
were summarized by cycle in the ITT population. The primary prespeci-
fied PRO end point was HRQOL assessed by the FACT-B total score.
Other PRO end points included FACT-G total score, FACT-G subscale
scores, BCS, TOI, EQ-5D index score, and EQ-VAS general health status
score. For each questionnaire (FACT-B and EQ-5D), a completion status
table was generated showing the numbers and percentages of patients at
each visit and the numbers and percentages of patients completing1
item of the questionnaire at that cycle. Changes from baseline in total
FACT-B and subscale scores occurring during treatment were assessed by
subtracting baseline QOL score from follow-up visit scores. The primary
prespecified PRO analysis to compare the 2 treatment groups was based
on a longitudinal, mixed-effects, random-intercept, random-slopemodel
[9]. The variables in the model are treatment, time, treatment by time,
and baseline used as covariates. In fitting the mixed-effects model, time
was used as a continuous variable and themethod of restrictedmaximum
likelihood was used and an unstructured covariance matrix was assumed.
A linear function was used because the slope of line graph across
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timepoints was linear and the time trend did not differ by treatment as-
signment. Similar analyses were carried out to compare the overall EQ-
5D index and VAS scores between treatment arms. No adjustments for
multiple comparisons were made.
As part of the post hoc analyses, an examination of the time to deteri-
oration (TTD) in FACT-B total score was conducted using survival
analysis methods including Kaplan–Meier plots, calculation of HRs, and
log-rank tests to compare the two treatment arms. TTD was defined as
the duration between baseline and first occurrence of a decrease of7
points in FACT-B score with no subsequent observation of a <7-point
decrease. In addition, TTD in FACT-B scores was compared between the
following groups in both treatment arms combined as well as in each
treatment arm separately: patients with versus without objective response
[complete response or partial response according to Response Evaluation
Criteria in Solid Tumors (RECIST) v 1.1] and patients with a progression
event versus those who did not progress. Although a one-sided test at a
significance level of 0.05 was used for consistency with the primary and
key secondary time-to-event end points, the critical value used for inter-
pretation for TTDwas 0.025.
In addition, as part of post hoc analyses, the change from baseline in
the individual item assessing pain in body parts was carried out using
repeated-measures mixed-effects analyses with baseline as a covariate. To
assess the effect of neutropenia, patients with and without neutropenia
were identified at each cycle and compared on change from baseline
FACT-B and observed EQ-5D index scores using analysis of variance
with baseline as a covariate. This analysis was carried out only for the pa-
tients in the palbociclib plus letrozole arm as few patients in the placebo
plus letrozole arm had neutropenia.
All analyses were conducted using Statistical Analysis System software
(SAS Institute, Cary, NC). All P values are two-sided unless stated
otherwise.
Results
Patients and disease characteristics
Baseline characteristics in the ITT population were well-balanced
between the two treatment arms as previously reported [4]. Mean
age was 62 years in the palbociclib plus letrozole arm and 61 years
in the placebo plus letrozole arm (supplementary Table S1, avail-
able at Annals of Oncology online). A total of 338 (76.1%) and 171
(77.0%) patients had measurable disease at baseline in the palbo-
ciclib plus letrozole and placebo plus letrozole arms, respectively.
Most patients in both treatment arms had Eastern Cooperative
Oncology Group performance status of 0 or 1 (98%). More than
one third of patients in each treatment arm had de novo disease
and about 40% had 3 or more metastatic sites (supplementary
Table S1, available at Annals of Oncology online).
Completion rates of PROs
The percentage of patients completing at least 1 question from
baseline to cycle 37 for FACT-B ranged from 95% to 100% in
each treatment arm except for cycle 33 in the placebo plus letro-
zole arm, where an 80% completion rate was observed among 5
eligible patients (at the time of data cut-off with 22.3months me-
dian follow-up). A summary of completion rates for FACT-B by
treatment arm and cycle and the number of eligible patients avail-
able to complete the questionnaire is presented in supplementary
Table S2, available at Annals of Oncology online; reasons for dis-
continuation overall and by treatment arm are presented in sup-
plementary Table S3, available at Annals of Oncology online.
FACT-B total scores
Baseline mean [6standard deviation (SD)] scores for FACT-B
total scores were similar for the palbociclib and the placebo plus
letrozole arms (101.56 19.1 versus 103.26 18.7) and compar-
able to healthy individuals (Table 1) [10]. The overall change
from baseline in FACT-B scores from the repeated-measures
mixed-effects model was not found to be significantly different
(P¼ 0.782) between the palbociclib plus letrozole arm [0.11
(95% CI1.42 to 1.21)] and the placebo plus letrozole arm [0.22
(1.68 to 2.12)]; the treatment-by-time interaction term was not
found to be significant (P¼ 0.610). The change from baseline
value did not reach the threshold of seven points in either treat-
ment arm indicating that addition of palbociclib to letrozole did
not have a clinically meaningful adverse impact on patient QOL.
A Forest plot of between-treatment comparisons of change from
baseline in total FACT-B and subscale scores is displayed in Figure 1.
FACT-G total and subscale scores
Baseline mean (6SD) scores for FACT-G total scores were simi-
lar for the palbociclib plus letrozole arm and placebo plus letro-
zole arm (77.76 15.5 versus 79.16 15.4; Table 1). The overall
change from baseline in FACT-G scores was not found to be sig-
nificantly different (P¼0.883) between the palbociclib plus letro-
zole [0.39 (95% CI 1.46 to 0.68)] and placebo plus letrozole
[0.53 (2.08 to 1.02)] treatment arms (Figure 1).
The overall change from baseline scores for PWB for the palbo-
ciclib plus letrozole arm versus the placebo plus letrozole arm was
not found to be statistically significantly different between the
two treatment arms [0.50 (95% CI 0.90 to 0.20) versus
0.30 (0.80 to 0.30)], SWB [0.60 (1.00 to 0.20) versus
0.70 (1.20 to 0.10)], EWB [0.70 (0.40–1.00) versus 0.50
(0.10–0.90)], and FWB [0.20 (0.20 to 0.60) versus 0.30 (0.30
to 0.90)]. Similarly no statistically significant difference was
observed in overall change from baseline in the BCS [0.19 (95%
CI 0.18 to 0.56) versus 0.83 (0.29 to 1.37)] and FACT-B TOI
[0.10 (1.00 to 0.81) versus 0.71 (0.61 to 2.02)] scores be-
tween the palbociclib plus letrozole and the placebo plus letrozole
arms (Figure 1). The treatment-by-time interaction term was not
statistically significant in models for any scale (except for emo-
tional functioning) indicating a similar time trend for PRO scores
for both arms after adjusting for covariates. A significantly greater
improvement from baseline was observed in the scores of the
item assessing pain in body parts [0.256 (95% CI 0.33 to
0.18) versus0.098 (0.21 to 0.01); P¼ 0.018].
Time to deterioration analyses
An analysis of TTD in FACT-B showed a positive trend (HR< 1)
favoring the palbociclib plus letrozole arm but was not statistic-
ally significant [HR: 0.883 (95% CI 0.6731.158); one-sided
P¼0.1900]. A Kaplan–Meier graph is provided in Figure 2A.
Time to deterioration analyses based on
progression status and objective response
The TTD analysis by progression status demonstrated a signifi-
cantly greater TTD in HRQOL as assessed by the FACT-B total
score in patients who had not progressed compared with those
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who did in the palbociclib plus letrozole arm (HR: 0.53; one-
sided P< 0.001; supplementary Figure S2A, available at Annals of
Oncology online) and the placebo plus letrozole arm (HR: 0.57;
one-sided P¼ 0.009; supplementary Figure S2B, available at
Annals of Oncology online) as well as in both treatment arms com-
bined (HR: 0.53; one-sided P< 0.001; supplementary Figure
S2C, available at Annals of Oncology online).
The TTD analysis of patients with an objective response com-
pared with those without demonstrated a significantly greater
TTD in HRQOL as assessed by the FACT-B total score in re-
sponders compared with non-responders. This was true based on
individual treatment arms: in the palbociclib plus letrozole arm
(HR: 0.410; one-sided P< 0.0001; Figure 2B) and in the placebo
arm (HR: 0.553; one-sided P¼ 0.0064; Figure 2C) as well as based
on all patients (HR: 0.452; one-sided P< 0.0001; Figure 2D).
EQ-5D health state profile
The percentage of patients reporting ‘extreme problems’ for any
descriptors was low in both treatment arms at baseline (Table 2)
and did not change notably from baseline over the course of
treatment.
2
Favors palbociclib + letrozoleFavors placebo + letrozole
10–1–2–3–4 3 4
Estimate
FACT-B total score
FACT-G total score
TOI score
Breast cancer subscale
Functional well-being
Emotional well-being
Social/family well-being
Physical well-being
Scales
–0.3253 (–2.63, 1.98)
0.1423 (–1.74, 2.03)
–0.8016 (–2.40, 0.79)
–0.6394 (–1.29, 0.01)
0.1675 (–0.37, 0.70)
–0.1303 (–0.81, 0.55)
0.1027 (–0.56, 0.77)
–0.2614 (–0.89, 0.37)
Estimate (95% CI)
Figure 1. Between-treatment comparison of overall change from baseline in FACT-B scores. FACT-B, Functional Assessment of Cancer
Therapy-Breast; FACT-G, Functional Assessment of Cancer Therapy-General; TOI, Trial Outcome Index.
Table 1. Baseline FACT-B scores
Domain Palbociclib1 letrozole
Mean (SD)
Placebo1 letrozole
Mean (SD)
Normative scores [10]
Mean (SD)
Physical well-being 21.9 (5.5) 21.8 (5.4) 22.1 (5.4)
Social/family well-being 21.8 (5.9) 22.2 (5.6) 19.8 (6.8)
Emotional well-being 16.3 (4.7) 16.6 (4.7) 19.4 (5.1)
Functional well-being 17.5 (6.0) 18.3 (6.0) 18.3 (6.9)
Breast cancer subscale 24 (5.6) 24.2 (5.5) NA
Trial Outcome Index 63.4 (13.6) 64.3 (13.3) NA
FACT-G total 77.7 (15.5) 79.1 (15.4) 79.6 (18.6)
FACT-B total 101.5 (19.1) 103.2 (18.7) NA
Pain 1.8 (1.3) 1.8 (1.3) NA
For FACT-B total, FACT-G total, and each of the subscales, a higher score indicates better well-being or quality of life. For the pain item, higher scores indi-
cate greater pain severity. FACT-B, Functional Assessment of Cancer Therapy-Breast; FACT-G, Functional Assessment of Cancer Therapy-General; NA, not
available; SD, standard deviation.
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EQ-5D index and VAS scores
Baseline EQ-5D index scores were similar between the palbociclib
plus letrozole and the placebo plus letrozole arms (Table 2).
Based on the longitudinal mixed-effects models, no statistically
significant differences were observed in the overall EQ-5D index
score on treatment between the palbociclib plus letrozole and pla-
cebo plus letrozole arms [0.74 (95% CI 0.72–0.75) versus 0.71
(0.69–0.73); P¼ 0.093].
Baseline EQ-5D VAS scores were also found to be similar be-
tween both study arms, and no statistically significant difference
was observed between treatment arms during treatment [75.07
(95%CI 73.87–76.27) versus 75.25 (73.51–76.99)] (Table 2).
FACT-B and EQ-5D index scores between patients
with and without neutropenia in the palbociclib
plus letrozole arm
No statistically significant differences were observed in the change
from baseline in FACT-B total score at any cycle between patients
with and without neutropenia in the palbociclib plus letrozole arm
(supplementary Figure S3, available at Annals of Oncology online).
No statistically significant differences were observed in the EQ-5D
index score at any cycle between patients with and without neutro-
penia except cycles 11, 13, and 15 (P< 0.05), in which the scores
were higher in the patients with neutropenia (supplementary
Figure S4, available atAnnals of Oncology online).
Discussion
Hormone receptor-positive (HRþ) MBC is not curable but can
have a long natural history with multiple lines of sequential effect-
ive regimens. For this reason, it is critical when introducing new
therapies with increased efficacy to demonstrate that QOL is not
compromised. Although treatment can prolong time to disease
progression, thereby forestalling the effects of disease, toxicity asso-
ciated with treatment can adversely affect QOL. In general, patients
receiving first-line therapy for HRþ/HER2 disease have a high
functional level of QOL at the time of diagnosis, comparable to the
general healthy population, and our current analysis provides con-
firmation of this finding. It is therefore even more important to
understand the effect of treatment on patients’ overall QOL, and
balance risk versus benefit. In the current study, we utilized two
widely known and validated PRO questionnaires, one assessing
breast cancer-specific HRQOL (FACT-B) and the other assessing
general health status (EQ-5D). To our knowledge, the results pre-
sented here represent the longest period of follow-up to date in the
published literature on PROs in women receiving endocrine-based
therapy for HRþ/HER2 MBC in the most contemporary care
setting. This analysis shows that women on endocrine therapy are
doing exceedingly well as evaluated by PROs, comparable to
healthy individuals [10].More importantly, results of outcomes as-
sessed using FACT-B showed maintenance of QOL in both arms,
without detriment from the addition of palbociclib.
Similar to the FACT-B total scores, the general health status
scores assessed using the EQ-5D VAS suggest that the addition of
palbociclib to letrozole does not have a significant adverse impact
on a patient’s health status compared with letrozole alone. A sig-
nificantly greater improvement in pain scores was observed in the
Figure 2. Time to deterioration in Functional Assessment of Cancer
Therapy-Breast (FACT-B) score. Between-treatment comparison of
time to deterioration in FACT-B score among all patients (A),
comparison of time to deterioration in FACT-B score between
responders and non-responders (based on objective response
status) in (B) the palbociclib plus letrozole arm, (C) the placebo plus
letrozole arm, and (D) both treatment arms combined. CI, confidence
interval; mo, months; NE, not estimable; NR, not reached.
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palbociclib plus letrozole arm. These results are consistent with
an earlier report for the palbociclib plus fulvestrant regimen as
later-line therapy [11].
Overall, maintenance of QOL in patients with MBC, at a level
close to healthy individuals in the general population with a me-
dian duration of treatment of almost 2 years is a significant im-
provement over previous therapies, including targeted therapy
over similar or shorter periods of time, and is clinically meaning-
ful for patients [12].
In both arms, deterioration of FACT-B Total score was signifi-
cantly delayed in patients without progression versus those with
progression and patients with partial or complete response versus
those without. It is worth noting that disease progression and
tumor response in this study were assessed by RECIST, which is
heavily reliant on radiographic imaging assessment. These data
emphasize the value of radiological assessment on treatment ef-
fect and are supported by patients’ direct reported outcomes
demonstrating the impact of differences in progression and re-
sponse status (a physician-reported outcome) and QOL. The
knowledge obtained from this analysis will add to the ongoing de-
bate in the medical community regarding the implications of
radiologically assessed versus clinically assessed disease progres-
sion for clinical practice and research.
Neutropenia is the main treatment-related adverse event asso-
ciated with CDK4/6-based therapy, requiring complete blood
count monitoring in the palbociclib plus letrozole arm; however,
neutropenia has been shown to have a neutral and/or no negative
impact, if any, on patients’ QOL (supplementary Figures S3 and
S4, available at Annals of Oncology online).
Potential limitations in the design of PRO analyses should be
considered when interpreting these results. The assumption that
missing data were missing at random in the PRO analysis may be
incorrect, and bias could occur as a result. To address this limita-
tion, the mixed-model approach was chosen because it is robust
as long as the proportion of missing data that cannot be ignored
is reasonably small (<5%) as was the case in this study.
Despite these limitations, the patient-reported QOL in this
study provides clear evidence about a critical component of the
risk-benefit profile from first-line palbociclib plus letrozole.
These data demonstrate that overall QOL in patients receiving
first-line endocrine-based therapy is maintained at high level,
and that patients’ QOL is not negatively affected by the addition
of palbociclib to letrozole. Maintenance of QOL close to general
healthy population norms for more than 2 years is clinically
meaningful. In conclusion, the addition of palbociclib to letro-
zole significantly improves PFS while maintaining HRQOL and
general health status in treatment-naı¨ve, postmenopausal women
with ERþ/HER2MBC. This observation is maintained regard-
less of the occurrence of neutropenia while deterioration of QOL
is delayed in patients with response and/or no progression.
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Table 2. EQ-5D scores at baseline and overall on treatment scores
Palbociclib1 letrozole (n5437) Placebo1 letrozole (n5 218)Health state (at baseline)
n No problem
n (%)
Some
problem
n (%)
Extreme
problem
n (%)
n No problem
n (%)
Some
problem
n (%)
Extreme
problem
n (%)
Mobility 436 268 (61.5) 166 (38.1) 2 (0.5) 215 132 (61.4) 83 (38.6) 0
Self-care 436 383 (87.8) 50 (11.5) 3 (0.7) 215 189 (87.9) 25 (11.6) 1 (0.5)
Usual activities 436 244 (56.0) 173 (39.7) 19 (4.4) 215 131 (60.9) 78 (36.3) 6 (2.8)
Pain/discomfort 436 135 (31.0) 277 (63.5) 24 (5.5) 215 76 (35.3) 132 (61.4) 7 (3.3)
Anxiety/depression 436 202 (46.3) 212 (48.6) 22 (5.0) 215 99 (46.0) 111 (51.6) 5 (2.3)
EQ-5D index scorea Mean SD 95% CI Mean SD 95% CI
Baseline 436 0.697 0.25 0.67–0.72 215 0.730 0.21 0.70–0.76
Overall on treatmentb NA 0.736 NA 0.72–0.75 NA 0.712 NA 0.69–0.73
End of treatment 181 0.630 0.30 0.59–0.67 129 0.662 0.30 0.61–0.71
EQ-5D VASa
Baseline 432 71.3 21.16 69.3–73.3 216 72.3 19.83 69.7–75.0
Overall on treatmentb NA 75.07 NA 73.87–76.27 NA 75.25 NA 73.51–76.99
End of treatment 181 68.0 21.81 64.8–71.2 131 70.1 21.11 66.5–73.8
aHigher EQ-5D index and VAS scores indicate better health status/quality of life.
bEstimated from a repeated-measures mixed-effects model with baseline, treatment, time, and treatment time interaction terms as covariates.
CI, confidence interval; EQ-5D, EuroQOL 5 dimensions questionnaire; SD, standard deviation; VAS, visual analog scale.
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